Integral Diagnostics Ltd
ASX:IDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Integral Diagnostics Ltd
ASX:IDX
|
AU |
|
Australian Clinical Labs Ltd
ASX:ACL
|
AU |
|
Rhythm Biosciences Ltd
ASX:RHY
|
AU |
|
Gujarat Fluorochemicals Ltd
NSE:FLUOROCHEM
|
IN |
|
Anupam Rasayan India Ltd
NSE:ANURAS
|
IN |
Wall Street
Price Targets
IDX Price Targets Summary
Integral Diagnostics Ltd
According to Wall Street analysts, the average 1-year price target for
IDX
is 3.18 AUD
with a low forecast of 2.06 AUD and a high forecast of 3.99 AUD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is IDX's stock price target?
Price Target
3.18
AUD
According to Wall Street analysts, the average 1-year price target for
IDX
is 3.18 AUD
with a low forecast of 2.06 AUD and a high forecast of 3.99 AUD.
What is Integral Diagnostics Ltd's Revenue forecast?
Projected CAGR
13%
For the last 11 years the
compound annual growth rate for
Integral Diagnostics Ltd's revenue is
24%.
The projected
CAGR
for the next 3 years is
13%.
What is Integral Diagnostics Ltd's Operating Income forecast?
Projected CAGR
28%
For the last 11 years the
compound annual growth rate for
Integral Diagnostics Ltd's operating income is
17%.
The projected
CAGR
for the next 3 years is
28%.
What is Integral Diagnostics Ltd's Net Income forecast?
Projected CAGR
143%
For the last 11 years the
compound annual growth rate for
Integral Diagnostics Ltd's net income is
-2%.
The projected
CAGR
for the next 3 years is
143%.
